Hydrogel-based biological delivery vehicle
A hydrogel-based biological delivery vehicle used to effectively deliver drug and biological material to tissue or organ sites. More specifically, a hydrogel binding matrix having a biopolymer backbone containing carboxyl groups. Tyramine may be substituted for at least a portion of the carboxyl groups, so that, when hydrogen peroxide is added, it causes creation of covalent bonds between tyramine molecules and cross-links the hydrogel binding matrix, thereby enabling the hydrogel binding matrix to transition from liquid to gel state. The hydrogel binding matrix, in its liquid form, is capable of encapsulating drug reservoirs to create a homogenous liquid with evenly distributed particles containing drugs or target molecules. As the hydrogel binding matrix solidifies into a gel state, the newly created cross-links do not disrupt or react with the drugs or target molecules contained within the drug reservoirs. This hydrogel-based biological delivery vehicle can be used in several medical applications.
1. A hydrogel-based drug delivery vehicle for delivering a drug to a wound comprising:
a) a first hydrogel matrix comprising a solvent and a plurality of chains of a first biopolymer dissolved in the solvent, the first biopolymer having a structure:
wherein n is an integer greater than or equal to 220;
wherein R is COOH or tyramine and wherein from 0.5 mol % to 3.0 mol % of R of the first biopolymer is tyramine; and
wherein the solvent is water; and
b) a plurality of drug reservoirs dispersed throughout the first hydrogel matrix; and
c) a cross-linking agent, wherein the cross-linking agent cross links tyramines within the first hydrogel matrix.
2. The hydrogel-based drug delivery vehicle of claim 1 , the drug reservoirs comprise an analgesic.
3. The hydrogel-based drug delivery vehicle of claim 2 , wherein the analgesic is bupivacaine.
4. The hydrogel-based drug delivery vehicle of claim 1 , wherein each of the plurality of drug reservoirs comprise:
i) a second hydrogel matrix comprising a solvent and a plurality of chains of a second biopolymer comprising:
wherein n is an integer greater than or equal to 220;
wherein R 1 is COOH or tyramine and wherein the percentage of R 1 that are tyramine is greater than the percentage of R that are tyramine;
wherein a concentration of the second biopolymer relative to the second hydrogel is greater than the concentration of the first biopolymer relative to the first hydrogel; and
wherein the solvent is water; and
ii) an analgesic agent dispersed within the each of the plurality of drug reservoirs.
5. The hydrogel-based drug delivery vehicle of claim 4 ,
wherein the analgesic is bupivacaine.
6. The hydrogel-based drug delivery vehicle of claim 1 , further comprising horseradish peroxidase and wherein the cross-linking agent is hydrogen peroxide.
7. The hydrogel-based drug delivery vehicle of claim 1 , wherein the osmolality of the first hydrogel is higher than 295 mOsm/Kg.
8. The hydrogel-based drug delivery vehicle of claim 1 , wherein the first hydrogel swells upon implantation into the wound.
9. The hydrogel-based drug delivery vehicle of claim 8 , wherein the first hydrogel absorbs fluid from surrounding tissue upon implantation into the wound.
10. The hydrogel-based drug delivery vehicle of claim 8 , wherein the first hydrogel inhibits wound bleeding upon implantation into the wound.
11. A hydrogel-based drug delivery vehicle for delivering a drug to a wound comprising:
a) a first hydrogel matrix comprising a solvent and a plurality of chains of a first biopolymer dissolved in the solvent, the first biopolymer having a structure:
wherein n is an integer greater than or equal to 220;
wherein R is COOH or tyramine;
wherein the concentration of the biopolymer in the solvent is from 0.5 mol % to 5 mol % and wherein the osmolality of the first hydrogel matrix is higher than 295 mOsm/Kg; and
wherein the solvent comprises is water;
b) a plurality of drug reservoirs dispersed throughout the first hydrogel matrix, each of the plurality of drug reservoirs comprising:
i) a second hydrogel matrix comprising a solvent and a second biopolymer comprising:
wherein n is an integer greater than or equal to 220;
wherein R 1 is COOH or tyramine and wherein the mol percentage of R 1 that are tyramine is greater than the mol percentage of R that are tyramine;
wherein the concentration of the second biopolymer relative to the second hydrogel is greater than the concentration of the first biopolymer relative to the first hydrogel; and
wherein the solvent is water; and
ii) an analgesic agent dispersed within the each of the plurality of drug reservoirs; and
c) a cross-linking agent, wherein the cross-linking agent cross links tyramines within the first and second hydrogel matrix.
12. The hydrogel-based drug delivery vehicle of claim 11 , wherein 1.5 mol % of R is tyramine.
13. The hydrogel-based drug delivery vehicle of claim 12 , wherein the first hydrogel and second hydrogel swell upon implantation into the wound.
14. The hydrogel-based drug delivery vehicle of claim 13 , wherein the first hydrogel and second hydrogel absorb fluid from surrounding tissue upon implantation into the wound.
15. The hydrogel-based drug delivery vehicle of claim 13 , further comprising horseradish peroxidase and wherein the cross-linking agent is hydrogen peroxide.
16. A hydrogel-based drug delivery vehicle for delivering a drug to a wound comprising:
a) a first hydrogel matrix comprising a solvent and a plurality of chains of a first biopolymer dissolved in the solvent, the first biopolymer having a structure:
wherein n is an integer greater than or equal to 220;
wherein R is COOH or tyramine and wherein from 0.5 mol % to 3.0 mol % of R is tyramine;
wherein the osmolality of the first hydrogel matrix is higher than 295 mOsm/Kg; and
wherein the solvent comprises is water;
b) a plurality of drug reservoirs dispersed throughout the first hydrogel matrix, each of the plurality of drug reservoirs comprising:
i) a second hydrogel matrix comprising a solvent and a second biopolymer comprising:
wherein n is an integer greater than or equal to 220;
wherein R 1 is COOH or tyramine and wherein the percentage of R 1 that are tyramine is greater than the percentage of R that are tyramine;
wherein the concentration of the second biopolymer relative to the second hydrogel is greater than the concentration of the first biopolymer relative to the first hydrogel; and
ii) an analgesic agent dispersed within the each of the plurality of drug reservoirs; and
c) a cross-linking agent, wherein the cross-linking agent cross links tyramines within the first hydrogel matrix and second hydrogel matrix.
17. The hydrogel-based drug delivery vehicle of claim 16 , wherein the first hydrogel matrix and second hydrogel matrix swell upon implantation into the wound.
18. The hydrogel-based drug delivery vehicle of claim 17 , wherein the first hydrogel matrix and second hydrogel matrix absorb fluid from surrounding tissue upon implantation into the wound.